Fundraising Fox

Rapamycin Holdings

San Antonio, US · Founded 2012 · Delaware corporation · 1 known investors

Biotech

Founders & leadership

RH
Randy H GoldsmithExecutive
MH
Mark HorseySecretary and Chief Financial Officer

Board

SD
Stephen DufilhoChairman of the Board of Directors

Investors · 1

UT Horizon FundreportedAustin

Reported raises · per SEC filings

Form D private placements

$1.4M disclosed across 1 of 6 rounds · 2013–2019

▶$7MofferedJun 2019 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen DufilhoDirector
  • Spangler Vaughn CaroleExecutive Officer
  • Mark HorseyExecutive Officer
Offering amount
$7M
Minimum investment
$100K
Proceeds to insiders
$450K
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1.5MofferedFeb 2018 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen DufilhoDirector
  • Mark HorseyExecutive Officer
  • Hargrove DanExecutive Officer
Offering amount
$1.5M
Minimum investment
$100K
Proceeds to insiders
$250K
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$3.5MofferedAug 2017 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen DufilhoDirector
  • Mark HorseyExecutive Officer
  • Hargrove DanExecutive Officer
Offering amount
$3.5M
Minimum investment
$100K
Proceeds to insiders
$250K
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2MofferedApr 2016 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Randy H GoldsmithExecutive Officer, Director
  • Stephen DufilhoDirector
  • Mark HorseyExecutive Officer
Offering amount
$2M
Minimum investment
$100K
Proceeds to insiders
$200K
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$2.5MofferedJul 2014 · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Stephen DufilhoDirector
  • Randy H GoldsmithExecutive Officer, Director
  • Mark HorseyExecutive Officer
Offering amount
$2.5M
Minimum investment
$100K
Proceeds to insiders
$120K
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$1.4MraisedFeb 2014 · 18 investors · Pharmaceuticals
Rule 506(c)
Officers, directors & promoters on the filing
  • Mark HorseyExecutive Officer
  • Randy H GoldsmithExecutive Officer, Director
  • Stephen DufilhoDirector
Offering amount
$1.4M
Amount sold
$1.4M
Minimum investment
$44.1K
Proceeds to insiders
$80K
First sale
Jul 2013
Incorporated
Corporation, Delaware, 2012
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

CPRIT awards $3 million to Emtora Biosciences, formerly called Rapamycin Holdings. - Barshop Institutebarshopinstitute.uthscsa.edu · Sep 2019New CEO Takes Over Rapamycin, Leads Funding Round With Plans for IND - BioSpacebiospace.com · Aug 2017Drug designed in San Antonio fights age-related diseasesexpressnews.com · Apr 2016Rapamycin raises $2.5M to advance lead drug for treating cancer in pets | Fierce Pharmafiercepharma.com · Jun 2015

Frequently asked questions

Who are Rapamycin Holdings's investors?
Rapamycin Holdings's investors include UT Horizon Fund.
How much funding has Rapamycin Holdings raised?
Rapamycin Holdings has disclosed $1.4M raised across 1 of its 6 known rounds.
Where is Rapamycin Holdings headquartered?
Rapamycin Holdings is headquartered in San Antonio, US.